1. Home
  2. PIII vs IRD Comparison

PIII vs IRD Comparison

Compare PIII & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PIII
  • IRD
  • Stock Information
  • Founded
  • PIII 2015
  • IRD 2018
  • Country
  • PIII United States
  • IRD United States
  • Employees
  • PIII N/A
  • IRD 14
  • Industry
  • PIII Medical/Nursing Services
  • IRD
  • Sector
  • PIII Health Care
  • IRD
  • Exchange
  • PIII Nasdaq
  • IRD NYSE
  • Market Cap
  • PIII 32.2M
  • IRD 36.3M
  • IPO Year
  • PIII N/A
  • IRD N/A
  • Fundamental
  • Price
  • PIII $0.20
  • IRD $1.15
  • Analyst Decision
  • PIII Buy
  • IRD Strong Buy
  • Analyst Count
  • PIII 3
  • IRD 1
  • Target Price
  • PIII $2.38
  • IRD $8.00
  • AVG Volume (30 Days)
  • PIII 5.6M
  • IRD 154.1K
  • Earning Date
  • PIII 03-27-2025
  • IRD 02-19-2025
  • Dividend Yield
  • PIII N/A
  • IRD N/A
  • EPS Growth
  • PIII N/A
  • IRD N/A
  • EPS
  • PIII N/A
  • IRD N/A
  • Revenue
  • PIII $1,476,630,000.00
  • IRD $8,381,000.00
  • Revenue This Year
  • PIII $21.45
  • IRD N/A
  • Revenue Next Year
  • PIII N/A
  • IRD $29.37
  • P/E Ratio
  • PIII N/A
  • IRD N/A
  • Revenue Growth
  • PIII 25.38
  • IRD N/A
  • 52 Week Low
  • PIII $0.17
  • IRD $0.81
  • 52 Week High
  • PIII $1.22
  • IRD $2.77
  • Technical
  • Relative Strength Index (RSI)
  • PIII 49.82
  • IRD N/A
  • Support Level
  • PIII $0.17
  • IRD N/A
  • Resistance Level
  • PIII $0.20
  • IRD N/A
  • Average True Range (ATR)
  • PIII 0.02
  • IRD 0.00
  • MACD
  • PIII 0.00
  • IRD 0.00
  • Stochastic Oscillator
  • PIII 65.71
  • IRD 0.00

About PIII P3 Health Partners Inc.

P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: